Source: Pixabay.com

MN-166 (Ibudilast) Shows Promise for CIPN

Post author:Jessica Lynn
Post published:September 30, 2020
Post category:Chemotherapy-induced peripheral neuropathy Rare Disease

Early last week, biopharmaceutical company MediciNova Inc. ("MediciNova") announced promising results for their therapeutic candidate MN-166 (ibudilast). The company, which published in the findings in Cancer Chemotherapy and Pharmacology, explored…

Get Involved

This Men's Health Awareness month, share your authentic story with others. Raise awareness and inspire change!

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Get Involved

MN-166 (Ibudilast) Shows Promise for CIPN

Metastatic Breast Cancer: Navigating Grief

Rethinking What It Means to Live With Acromegaly

The Let’s Chat CAR T One-on-One Mentor Program: Speaking with Someone Who Understands What You Are Going Through

Get Involved

Let’s Work Together!

Keep Up to Date

Learn More